Áttétes emlőrák: vizsgálatok itt: Kína
224 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleTrastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 53
- Run by
- Fudan University
See details and how to joinNCT07647016 - 3. fázisTaking peopleTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Where
- Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00 - 2. fázisNot yet taking people in KínaExploratory Study of SHR-A1811 Via Different Administration Routes in Patients
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07560475 - No phaseTaking peopleA Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 100
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06839547 - No phaseTaking peopleThe Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 324
- Run by
- Fudan University
See details and how to joinNCT07638774 - No phaseTaking peopleA Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 150
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06776861 - 2. fázisNot yet taking people in KínaEfficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07630103 - 3. fázisTaking peopleA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Where
- Chengdu, Guangzhou
- Életkor
- 18 év to 75 év
- People
- 596
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07518173 - 3. fázisTaking peopleTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Where
- Anyang, Baoji, Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Guiyang, Haikou, Hanzhong, Harbin, Hefei, Jiamusi, Jinan, Jingmen, Kunming, Lanzhou, Linyi, Liuzhou, Luoyang, Luzhou, Mudanjiang, Nanchang, Nanchong, Nanjing, Nanning, Nanyang, Ningbo, Qinhuangdao, Shenyang, Shenzhen, Shijiazhuang, Suining, Suzhou, Taiyuan, Tangshan, Tianjin, Ürümqi, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Yibin, Yinchuan, Yongzhou, Yuncheng, Zhangjiajie, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 416
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT07047365 - 3. fázisTaking peopleA Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 912
- Run by
- Shandong Suncadia Medicine Co., Ltd.
See details and how to joinNCT07354022 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 201
- Run by
- Shenzhen Ionova Life Sciences Co., Ltd.
See details and how to joinNCT07612891 - 2. fázisTaking peopleDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Where
- Guangdong
- Életkor
- 18 év to 75 év
- People
- 57
- Run by
- Sun Yat-sen University
See details and how to joinNCT07610720 - 3. fázisTaking peopleYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 376
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07461454 - No phaseTaking peopleEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Where
- Changde, Changsha, Dongguan, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Hohhot, Nanjing, Shanghai, Shantou, Shaoguan, Shenzhen, Zhongshan, Zhuhai
- Életkor
- 18 év to 80 év
- People
- 800 worldwide
- Run by
- Sun Yat-sen University
See details and how to joinNCT06551220 - No phaseTaking peopleRC48-ADC in HER2-low Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 36
- Run by
- RenJi Hospital
See details and how to joinNCT05831878 - 2. fázisTaking peopleA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 150
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07497386 - 3. fázisTaking peopleStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 376
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT06081959 - 3. fázisTaking peopleA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
- Where
- Beijing, Guangzhou
- Életkor
- 18 év to 75 év
- People
- 430
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07071337 - 2. fázisTaking peopleSac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Sun Yat-sen University
See details and how to joinNCT07258108 - 2. fázisTaking peopleA Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Where
- Zhenzhou
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07299825 - 2. fázisNot yet taking people in KínaBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 46
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07539753 - 1/2. fázisNot yet taking people in KínaA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
- Where
- Beijing, Chengdu, Harbin
- Életkor
- 18 év to 75 év
- People
- 286
- Run by
- Akeso
See details and how to joinNCT07560124 - No phaseTaking peopleReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT07551050 - 3. fázisTaking peoplePhase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Where
- Changsha, Guangzhou, Guiyang, Shanghai, Wuhan, Yichang, Yongzhou
- Életkor
- 18 év to 70 év
- People
- 246
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06889688 - 2. fázisTaking peopleA Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 92
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07540533